Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 10, 2018December 10, 2018

New Analysis Confirms Hemlibra’s Sustained Efficacy in Controlling Bleeding in Some Children With Hemophilia A

News

A new analysis of the Phase 3 HAVEN 2 study’s results shows that Genentech’s Hemlibra (emicizumab-kxwh) prophylaxis (preventive treatment) leads to significant reductions in the number of bleeds among hemophilia A children younger ... Read more

August 31, 2018August 31, 2018

FDA Approves Bayer’s Jivi for Hemophilia A Patients 12 and Older

News

The U.S. Food and Drug Administration has approved Bayer’s Jivi, previously known as BAY94-9027, as a preventive therapy for hemophilia A in patients ages 12 and older, the company announced. The ... Read more

June 27, 2018June 27, 2018

CB 2679d Brings Clotting Protein Levels Closer to Normal in Hemophilia B Patients, Phase 1/2 Data Show

News

Treatment with CB 2679d increased factor IX activity levels in the blood, bringing them closer to normal levels in the newest group of patients with severe hemophilia B in the Phase 1/2 ... Read more

June 15, 2018June 15, 2018

Data Supports Potential for Personalized Hemophilia A Therapy with Nuwiq, WFH Presentations Show

News

Since every hemophilia A patient responds differently to therapies, researchers are working to develop personalized preventive (prophylaxis) strategies with Nuwiq (antihemophilic factor .) Octapharma, the treatment’s manufacturer, presented data showing that ... Read more

June 13, 2018June 13, 2018

Hemophilia Patients Want to Lead More Active Lives, Survey Results Indicate

News

Preliminary results from the U.S. part of Bayer’s global HemACTIVE patient survey show that a majority of hemophilia patients want to be more active but are limited in their ... Read more

May 25, 2018May 25, 2018

Hemlibra Looks to Reach ‘Ultimate Goal’ of Treating All with Hemophilia A and with Choice in Dosing, Genentech Director Says

News

Should regulatory authorities agree with favorable results from Genentech’s ongoing Phase 3 studies of Hemlibra (emicizumab-kxwh), hemophilia A patients may have a treatment they can use regardless of inhibitor status, with ... Read more

May 23, 2018May 23, 2018

Hemlibra Ably Treats Hemophilia A Patients Regardless of Inhibitor Status, Data from 2 Phase 3 Trials Show

News

Data from ongoing Phase 3 clinical trials show that Genentech’s Hemlibra (emicizumab-kxwh) prophylaxis — or preventive treatment — greatly outperforms current standard-of-care therapies, leading to significant reductions in the ... Read more

May 16, 2018May 16, 2018

Valoctocogene Roxaparvovec Study Doses 1st Hemophilia Patient with Pre-existing AAV5 Antibodies

News

A Phase 1/2 trial (NCT03520712) testing BioMarin Pharmaceutical’s investigational gene therapy valoctocogene roxaparvovec in severe hemophilia A patients with pre-existing AAV5 antibodies has dosed its first participant. “Administration of valoctocogene ... Read more

May 11, 2018May 11, 2018

IV Self-Infusion Training Significantly Reduced Infections After Joint Replacement Surgery

News

Teaching hemophilia patients who have undergone joint replacement surgery how to administer their intravenous (IV) self-infusions in sterility, can decrease the rate of infections post-surgery significantly, a six-year education ... Read more

March 23, 2018March 23, 2018

Hemlibra is an Effective and Cost-saving Hemophila A Therapy, Report Finds

News

Hemlibra (emicizumab) is an effective and less costly therapy for hemophilia A patients who have substances in their blood that prevent clotting factor therapies from working as well as they ... Read more

Pin It on Pinterest